マルチプレックスアッセイ市場：製品・サービス（消耗品、機器、ソフトウェア＆サービス）、タイプ（核酸、タンパク質）、技術（フローサイトメトリー、発光）、用途（研究開発、診断）、エンドユーザー（製薬、病院）-2027年までの世界予測

Multiplex Assays Market by Product & Service (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma, Hospitals) - Global Forecast to 2027

マルチプレックスアッセイ市場は、2022年に推定35億米ドルと評価され、予測期間中に8.8%のCAGRで、2027年までに53億米ドルに達すると予測されています。慢性疾患の負担は、抑制と管理のためのマルチプレックスア... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年5月1日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	200	183	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

マルチプレックスアッセイ市場は、2022年に推定35億米ドルと評価され、予測期間中に8.8%のCAGRで、2027年までに53億米ドルに達すると予測されています。慢性疾患の負担は、抑制と管理のためのマルチプレックスアッセイの使用を必要としています。多くのバイオマーカーが発見され、検証されているため、新しい診断テストが開発される可能性が高くなっています。現在のところ、特定の疾患群を対象としたマルチプレックスアッセイは数種類に限られています。新しいバイオマーカーが開発されれば、新しいマルチプレックスアッセイを開発することができる。このため、バイオマーカーの検証は、マルチプレックスアッセイ市場の発展のための機会を創出することができます。しかし、装置のコストが高いことが、マルチプレックスアッセイの普及を制限する大きな要因となっています。
"マルチプレックスアッセイ市場において、製品・サービス別では消耗品分野が予測期間中に最も高い成長率を占めた"
製品・サービスに基づき、マルチプレックスアッセイ市場は、消耗品、機器、ソフトウェア＆サービスの3つに大別されます。2022年、消耗品セグメントは市場で最大のシェアを占めています。また、このセグメントは最も高いCAGRで成長すると予想されています。機器セグメントは、マルチプレックスアッセイ市場で2番目に大きなシェアを占めています。感染症やがんの発生率の増加、ハイスループット能力を備えた自動化された高度な機器への需要の高まり、最小限の人的介入でより迅速かつ正確な検査結果に対するニーズの高まりが、機器市場セグメントを牽引しています。
"マルチプレックスアッセイ市場において、予測期間中のアプリケーション別成長率は、研究開発分野が最も高い。"
マルチプレックスアッセイ市場は、アプリケーションに基づき、研究開発（創薬・開発、バイオマーカー探索・検証）と臨床診断（感染症、がん、心血管疾患、自己免疫疾患、神経系疾患、代謝・内分泌疾患、その他の疾患）に分類されます。2022年のマルチプレックスアッセイ市場では、研究開発用途セグメントが最大のシェアを占めています。2022年の研究・開発用マルチプレックスアッセイ市場では、創薬・開発分野が最大のシェアを占めた。創薬＆開発におけるマルチプレックスアッセイの需要は、その利点から増加しています。これらのアッセイは、薬剤開発の臨床段階における薬剤反応バイオマーカー、免疫療法の成功、毒性の評価に有効である傾向がある。

"アジア太平洋地域急成長地域のマルチプレックスアッセイ市場"
世界のマルチプレックスアッセイ市場は、北米、欧州、アジア太平洋地域、その他の地域に区分されます。アジア太平洋地域は、予測期間中に最も高いCAGRを記録すると予測されています。アジア太平洋地域は、病気の早期発見や定期的な健康診断の増加に関する意識を高めるための政府の取り組みの高まり、医療費の増加、インドや中国における病院や臨床診断ラボの数の増加、インド、中国、日本における診断手順の研究基盤の強化などの要因により、予測期間中に最も高い成長を示すと予想されます。

マルチプレックスアッセイ市場の主要参加者のプロファイルのブレークアップ：

- 企業タイプ別：Tier1：42％、Tier2：37％、Tier3：21％。
- 役職別Cレベル：34％、Dレベル：42％、その他：24
- 地域別では北米：32％、欧州：30％、アジア太平洋地域：24％、その他の地域：14
この市場の主要プレーヤーは、Illumina, Inc.（米国）、Thermo Fisher Scientific, Inc.（米国）、Bio-Rad Laboratories, Inc.（米国）、Becton、Dickinson and Company（米国）、DiaSorin S.p.A. （イタリア）、QIAGEN N.V.（オランダ）、Abcam plc（英国）、Merck KGaA（ドイツ）、Agilent Technologies, Inc.（米国）、Quanterix（米国）、Bio-Techne（米国）、MESO SCALE DIAGNOSTICS, LLC（米国）、Randox Laboratories Ltd.(英国）、Olink社（スウェーデン）、Seegene社（韓国）、Siemens Healthcare AG（ドイツ）、PerkinElmer社（米国）、島津製作所（日本）、Promega Corporation（米国）、Enzo Biochem Inc（米国）、Cayman Chemical（米国）、Boster Biological Technology（米国）、Antigenix America、Inc（米国）、Quanys Biosciences Inc（米国）、RayBiotech Life、Inc（米国）です。
調査対象範囲
この調査レポートは、マルチプレックスアッセイ市場を製品＆サービス（消耗品、機器、ソフトウェア＆サービス）、タイプ（タンパク質マルチプレックスアッセイ［プラナープロテインアッセイ、ビーズベースプロテインアッセイ、その他のタンパク質アッセイ］）で分類しています、核酸マルチプレックスアッセイ［プレーナー核酸アッセイ、ビーズベース核酸アッセイ、その他の核酸アッセイ］、セルベースマルチプレックスアッセイ）、技術（フローサイトメトリー、蛍光検出、発光、マルチプレックスリアルタイムPCR、その他の技術）、アプリケーション（研究開発［創薬・開発、バイオマーカー探索・検証］、臨床診断［感染症、がん、循環器疾患、自己免疫疾患、神経系疾患、代謝・内分泌疾患、その他の疾患］）、エンドユーザー（製薬・バイオテクノロジー企業、病院・研究機関、リファレンスラボ、その他のエンドユーザー）、地域（北米、欧州、アジア太平洋、その他の地域）。マルチプレックスアッセイ市場の成長に影響を与える推進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、買収、契約、新製品・サービスの発売、マルチプレックスアッセイ市場に関連する最近の動向に関する洞察を提供しています。マルチプレックスアッセイ市場のエコシステムにおける今後の新興企業の競争分析も本レポートで取り上げています。
本レポートを購入する理由
本レポートは、マルチプレックスアッセイ市場全体とサブセグメントの収益数の最も近い近似値に関する情報を提供し、本市場の市場リーダー/新規参入者の助けとなるものです。本レポートは、利害関係者が競争環境を理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、および機会に関する情報を提供します。
本レポートは、以下のポイントに関する洞察を提供します：
- コンパニオン診断におけるマルチプレックスアッセイの利用の増加、シングルプレックスや従来のアッセイに対する利点の増加、慢性疾患や感染症の発生率の増加、疾患の早期診断に関する意識の高まり）、阻害要因（機器のコスト上昇、厳しい規制や基準の増加）、機会（分子およびタンパク質診断におけるバイオマーカーの検証の増加、ハイスループットと自動システムのニーズの高まり）、マルチプレックスアッセイの市場成長に影響を及ぼす課題（熟練専門家が不足してきている）の主要因に関する解析
- 製品開発/イノベーション：マルチプレックスアッセイ市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 本レポートは、さまざまな地域のマルチプレックスアッセイ市場を分析しています。
- 市場の多様化：新製品・サービス、未開拓の地域、最近の開発、マルチプレックスアッセイ市場への投資に関する詳細な情報を提供します。
- 競合他社の評価マルチプレックスアッセイ市場戦略における、Illumina, Inc（米国）、Thermo Fisher Scientific, Inc（米国）、Bio-Rad Laboratories, Inc（米国）、Becton, Dickinson and Company（米国）、DiaSorin S.p.A. （イタリア）、および Merck KGaA（ドイツ）などの主要企業の市場シェア、成長戦略およびサービス提供について詳細に評価することができる。

ページTOPに戻る

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.3 STUDY SCOPE 28
1.3.1 REGIONAL SCOPE 28
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 29
1.5 UNITS CONSIDERED 29
1.6 LIMITATIONS 29
1.7 STAKEHOLDERS 30
1.8 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.2 RESEARCH APPROACH 32
FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY 32
2.2.1 SECONDARY DATA 33
2.2.1.1 Key data from secondary sources 34
2.2.2 PRIMARY DATA 35
2.2.2.1 Primary sources 35
2.2.2.2 Key data from primary sources 36
2.2.2.3 Key industry insights 37
2.2.2.4 Breakdown of primary interviews 37
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 38
2.3 MARKET SIZE ESTIMATION 38
2.3.1 BOTTOM-UP APPROACH 39
2.3.1.1 Approach 1: Company revenue estimation approach 39
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 39
2.3.1.2 Approach 2: Presentations of companies and primary interviews 39
2.3.1.3 Growth forecast 40
2.3.1.4 CAGR projections 40
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40
2.3.2 TOP-DOWN APPROACH 40
FIGURE 6 MULTIPLEX ASSAYS MARKET: TOP-DOWN APPROACH 41

2.4 MARKET BREAKDOWN & DATA TRIANGULATION 42
FIGURE 7 DATA TRIANGULATION 42
2.5 MARKET SHARE ANALYSIS 43
2.6 STUDY ASSUMPTIONS 43
2.7 LIMITATIONS 44
2.8 GROWTH RATE ASSUMPTIONS 44
2.9 RISK ASSESSMENT 45
2.9.1 RISK ASSESSMENT: MULTIPLEX ASSAYS MARKET 45
2.10 RECESSION IMPACT 45
3 EXECUTIVE SUMMARY 47
FIGURE 8 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION) 47
FIGURE 9 MULTIPLEX ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 48
FIGURE 10 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 48
FIGURE 11 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 49
FIGURE 12 MULTIPLEX ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 49
FIGURE 13 MULTIPLEX ASSAYS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 50
4 PREMIUM INSIGHTS 51
4.1 MULTIPLEX ASSAYS MARKET OVERVIEW 51
FIGURE 14 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH 51
4.2 MULTIPLEX ASSAYS MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027 51
FIGURE 15 CONSUMABLES PRODUCT & SERVICE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027 51
4.3 MULTIPLEX ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027 52
FIGURE 16 PROTEIN MULTIPLEX ASSAYS TYPE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE 52
4.4 MULTIPLEX ASSAYS MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027 52
FIGURE 17 FLOW CYTOMETRY TECHNOLOGY TO ACCOUNT FOR LARGEST MARKET SHARE 52
4.5 MULTIPLEX ASSAYS MARKET SHARE, BY APPLICATION, 2022 VS. 2027 53
FIGURE 18 RESEARCH & DEVELOPMENT APPLICATION TO ACCOUNT FOR LARGER MARKET SHARE 53
4.6 MULTIPLEX ASSAYS MARKET SHARE, BY END USER, 2022 VS. 2027 53
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES END USER SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE 53
4.7 MULTIPLEX ASSAYS MARKET: REGIONAL GROWTH OPPORTUNITIES 54
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 54

5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
FIGURE 21 MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
5.2.1 DRIVERS 56
5.2.1.1 Increasing use of multiplex assays in companion diagnostics 56
5.2.1.2 Increasing advantages over singleplex and traditional assays 56
5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 57
FIGURE 22 INCIDENCE OF DIABETES, BY REGION, IN 2021, 2030, AND 2045 58
TABLE 1 TOTAL HEALTH EXPENDITURE DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY 58
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 58
TABLE 3 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR DIAGNOSIS OF SARS-COV-2 59
5.2.2 RESTRAINTS 60
5.2.2.1 Rising costs of equipment 60
5.2.2.2 Growing number of stringent regulations and standards 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics 61
5.2.3.2 Rising need for high-throughput and automated systems 61
5.2.4 CHALLENGES 61
5.2.4.1 Increasing dearth of skilled professionals 61
TABLE 4 NUMBER OF LAB TECHNOLOGISTS AND TECHNICIANS IN US, 2020 62
5.3 CUSTOMIZATION DATA 62
TABLE 5 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 62
6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE 63
6.1 INTRODUCTION 64
TABLE 6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 64
6.2 PRIMARY NOTES 64
6.2.1 KEY INDUSTRY INSIGHTS 64
6.3 CONSUMABLES 64
6.3.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET 64
TABLE 7 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 65
TABLE 8 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
6.4 INSTRUMENTS 66
6.4.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH 66
TABLE 9 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 67
6.5 SOFTWARE & SERVICES 67
6.5.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE 67
TABLE 11 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 68
TABLE 12 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 68
7 MULTIPLEX ASSAYS MARKET, BY TYPE 69
7.1 INTRODUCTION 70
TABLE 13 MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70
7.2 PROTEIN MULTIPLEX ASSAYS 70
TABLE 14 PROTEIN MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 15 PROTEIN MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 16 NORTH AMERICA: PROTEIN MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 71
7.2.1 PLANAR PROTEIN ASSAYS 71
7.2.1.1 Pivotal role in drug discovery to support uptake 71
TABLE 17 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 18 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
7.2.2 BEAD-BASED PROTEIN ASSAYS 72
7.2.2.1 Best suited to study protein-protein interactions 72
TABLE 19 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 20 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
7.2.3 OTHER PROTEIN ASSAYS 73
TABLE 21 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 22 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
7.3 NUCLEIC ACID MULTIPLEX ASSAYS 74
TABLE 23 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA AND SARS-COV-2 75
TABLE 24 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 25 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 26 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78

7.3.1 PLANAR NUCLEIC ACID ASSAYS 78
7.3.1.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis 78
TABLE 27 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 28 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79
7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS 79
7.3.2.1 Increasing infectious diseases and genetic screening tests to drive market 79
TABLE 29 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 30 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.3.3 OTHER NUCLEIC ACID ASSAYS 80
TABLE 31 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 32 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.4 CELL-BASED MULTIPLEX ASSAYS 81
7.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET 81
TABLE 33 CELL-BASED MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 34 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY 82
8.1 INTRODUCTION 83
TABLE 35 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 83
8.2 FLOW CYTOMETRY 83
8.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO MAKE THIS MARKET SEGMENT LARGEST 83
TABLE 36 MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 37 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION) 84
8.3 FLUORESCENCE DETECTION 84
8.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL GROWTH 84
TABLE 38 MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 39 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2020–2027 (USD MILLION) 85
8.4 LUMINESCENCE 85
8.4.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET 85
TABLE 40 MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY REGION, 2020–2027 (USD MILLION) 86
TABLE 41 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY COUNTRY, 2020–2027 (USD MILLION) 86
8.5 MULTIPLEX REAL-TIME PCR 86
8.5.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS 86
TABLE 42 MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 43 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.6 OTHER TECHNOLOGIES 87
TABLE 44 MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 45 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION) 88
9 MULTIPLEX ASSAYS MARKET, BY APPLICATION 89
9.1 INTRODUCTION 90
TABLE 46 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 90
9.2 RESEARCH & DEVELOPMENT 90
TABLE 47 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 48 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 49 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 91
9.2.1 DRUG DISCOVERY & DEVELOPMENT 91
9.2.1.1 Multiplex assays massively employed in preclinical and clinical phases 91
TABLE 50 MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 51 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 92
9.2.2 BIOMARKER DISCOVERY & VALIDATION 92
9.2.2.1 Multiplex assays aid in quantitative measurement of protein biomarkers in large samples 92
TABLE 52 MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 53 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION) 93
9.3 CLINICAL DIAGNOSTICS 93
TABLE 54 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 55 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 56 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 94
9.3.1 INFECTIOUS DISEASES 95
9.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays 95
TABLE 57 MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 58 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 96
9.3.2 CANCER 96
9.3.2.1 Rising burden of cancer to drive market 96
TABLE 59 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 97
TABLE 60 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER 97
TABLE 61 MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 98
TABLE 62 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 98
9.3.3 CARDIOVASCULAR DISEASES 98
9.3.3.1 High burden of cardiovascular diseases to support market growth 98
TABLE 63 MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 99
TABLE 64 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 99
9.3.4 AUTOIMMUNE DISEASES 99
9.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis 99
TABLE 65 PREVALENCE OF SOME AUTOIMMUNE DISEASES 100
TABLE 66 MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 67 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 101
9.3.5 NERVOUS SYSTEM DISORDERS 101
9.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment 101
TABLE 68 MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION) 101
TABLE 69 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 102
9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS 102
9.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers that help in timely diagnosis of such conditions 102
TABLE 70 MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2020–2027 (USD MILLION) 102
TABLE 71 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9.3.7 OTHER DISEASES 103
TABLE 72 MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION) 103
TABLE 73 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 104
10 MULTIPLEX ASSAYS MARKET, BY END USER 105
10.1 INTRODUCTION 106
TABLE 74 MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 106
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 106
10.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE ITS UPTAKE 106
TABLE 75 MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 76 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 107
10.3 HOSPITALS & RESEARCH INSTITUTES 107
10.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET 107
TABLE 77 MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 108
TABLE 78 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 109
10.4 REFERENCE LABORATORIES 109
10.4.1 GROWING NUMBER OF CLINICAL TESTS PERFORMED IN REFERENCE LABORATORIES AND INCREASING NUMBER OF ACCREDITED LABORATORIES TO SUPPORT MARKET GROWTH 109
TABLE 79 MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 80 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 110
10.5 OTHER END USERS 110
TABLE 81 MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 111
TABLE 82 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 111
11 MULTIPLEX ASSAYS MARKET, BY REGION 112
11.1 INTRODUCTION 113
TABLE 83 MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 113
11.2 NORTH AMERICA 113
TABLE 84 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 85 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 114
TABLE 86 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 87 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 115
TABLE 88 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115
TABLE 89 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 116
FIGURE 23 NORTH AMERICA: MULTIPLEX ASSAYS MARKET SNAPSHOT 116
11.2.1 RECESSION IMPACT ON NORTH AMERICA 117
11.2.2 US 117
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market 117
TABLE 90 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 118
TABLE 91 US: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 92 US: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 119
TABLE 93 US: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
TABLE 94 US: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 119
11.2.3 CANADA 120
11.2.3.1 Increased funding activities by government in life sciences research & drug development to support market growth 120
TABLE 95 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 120
TABLE 96 CANADA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 97 CANADA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 121
TABLE 98 CANADA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 99 CANADA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 121
11.3 EUROPE 122
TABLE 100 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP) 123
TABLE 101 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 124
TABLE 102 EUROPE: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 103 EUROPE: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 124
TABLE 104 EUROPE: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
TABLE 105 EUROPE: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 125
11.3.1 RECESSION IMPACT ON EUROPE 125
11.4 ASIA PACIFIC 126
FIGURE 24 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET SNAPSHOT 127
TABLE 106 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 127
TABLE 107 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 128
TABLE 109 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 110 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
11.4.1 RECESSION IMPACT ON ASIA PACIFIC 129
11.5 REST OF THE WORLD 129
TABLE 111 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 130
TABLE 112 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 113 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 131
TABLE 114 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 115 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 132
11.5.1 RECESSION IMPACT ON REST OF THE WORLD 132
12 COMPETITIVE LANDSCAPE 133
12.1 OVERVIEW 133
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 133
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 133
TABLE 116 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES 133
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 135
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2017–2021) 135
12.4 MARKET SHARE ANALYSIS 135
12.4.1 MULTIPLEX ASSAYS MARKET 135
FIGURE 26 MULTIPLEX ASSAYS MARKET SHARE, BY KEY PLAYER, 2021 136
TABLE 117 MULTIPLEX ASSAYS MARKET: INTENSITY OF COMPETITIVE RIVALRY 136
12.5 COMPANY EVALUATION QUADRANT 137
12.5.1 LIST OF EVALUATED VENDORS 137
12.5.2 STARS 138
12.5.3 EMERGING LEADERS 138
12.5.4 PERVASIVE PLAYERS 138
12.5.5 PARTICIPANTS 138
FIGURE 27 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 139
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021) 139
12.6.1 PROGRESSIVE COMPANIES 139
12.6.2 STARTING BLOCKS 139
12.6.3 RESPONSIVE COMPANIES 140
12.6.4 DYNAMIC COMPANIES 140
FIGURE 28 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021 140

12.7 COMPETITIVE SCENARIO 141
12.7.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 141
TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020- 2023) 141
12.7.2 DEALS 142
TABLE 119 KEY DEALS (2020-2023) 142
13 COMPANY PROFILES 143
13.1 KEY PLAYERS 143
(Business Overview, Products Offered, Recent Developments, and MnM View)*
13.1.1 ILLUMINA, INC. 143
TABLE 120 ILLUMINA, INC.: BUSINESS OVERVIEW 143
FIGURE 29 COMPANY SNAPSHOT: ILLUMINA, INC. (2022) 144
13.1.2 BIO-RAD LABORATORIES, INC. 149
TABLE 121 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 149
FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2022) 150
13.1.3 THERMO FISHER SCIENTIFIC, INC. 154
TABLE 122 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 154
FIGURE 31 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC. (2021) 155
13.1.4 BECTON, DICKINSON AND COMPANY 158
TABLE 123 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW 158
FIGURE 32 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2022) 159
13.1.5 DIASORIN S.P.A. 162
TABLE 124 DIASORIN S.P.A.: BUSINESS OVERVIEW 162
FIGURE 33 COMPANY SNAPSHOT: DIASORIN S.P.A. (2021) 163
13.1.6 QIAGEN N.V. 165
TABLE 125 QIAGEN N.V.: BUSINESS OVERVIEW 165
FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2021) 166
13.1.7 ABCAM PLC 168
TABLE 126 ABCAM PLC.: BUSINESS OVERVIEW 168
FIGURE 35 COMPANY SNAPSHOT: ABCAM PLC (2021) 169
13.1.8 MERCK KGAA 172
TABLE 127 MERCK KGAA: BUSINESS OVERVIEW 172
FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2022) 173
13.1.9 AGILENT TECHNOLOGIES, INC. 176
TABLE 128 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 176
FIGURE 37 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2022) 177
13.1.10 QUANTERIX 179
TABLE 129 QUANTERIX: BUSINESS OVERVIEW 179
FIGURE 38 COMPANY SNAPSHOT: QUANTERIX (2022) 180
13.1.11 BIO-TECHNE 182
TABLE 130 BIO-TECHNE: BUSINESS OVERVIEW 182
FIGURE 39 COMPANY SNAPSHOT: BIO-TECHNE (2021) 183
13.1.12 MESO SCALE DIAGNOSTICS, LLC 185
TABLE 131 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW 185
13.1.13 RANDOX LABORATORIES LTD. 187
TABLE 132 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 187
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 189
13.2.1 OLINK 189
TABLE 133 OLINK: COMPANY OVERVIEW 189
13.2.2 SEEGENE INC. 190
TABLE 134 SEEGENE INC.: COMPANY OVERVIEW 190
13.2.3 SIEMENS HEALTHINEERS AG 191
TABLE 135 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 191
13.2.4 PERKINELMER INC. 192
TABLE 136 PERKINELMER INC.: COMPANY OVERVIEW 192
13.2.5 SHIMADZU CORPORATION 193
TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW 193
13.2.6 PROMEGA CORPORATION 194
TABLE 138 PROMEGA CORPORATION: COMPANY OVERVIEW 194
13.2.7 ENZO BIOCHEM INC. 195
TABLE 139 ENZO BIOCHEM INC.: COMPANY OVERVIEW 195
13.2.8 CAYMAN CHEMICAL 196
TABLE 140 CAYMAN CHEMICAL: COMPANY OVERVIEW 196
13.2.9 BOSTER BIOLOGICAL TECHNOLOGY 197
TABLE 141 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 197
13.2.10 ANTIGENIX AMERICA, INC. 198
TABLE 142 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW 198
13.2.11 QUANSYS BIOSCIENCES INC. 198
TABLE 143 QUANSYS BIOSCIENCES INC.: COMPANY OVERVIEW 198
13.2.12 RAYBIOTECH LIFE, INC. 199
TABLE 144 RAYBIOTECH LIFE, INC.: COMPANY OVERVIEW 199
14 APPENDIX 200
14.1 DISCUSSION GUIDE 200
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 203
14.3 CUSTOMIZATION OPTIONS 205
14.4 RELATED REPORTS 205
14.5 AUTHOR DETAILS 206

ページTOPに戻る

Table of Contents

Summary

The multiplex assays market is valued at an estimated USD 3.5 billion in 2022 and is projected to reach USD 5.3 billion by 2027, at a CAGR of 8.8% during the forecast period. The burden of chronic diseases has necessitated the use of multiplex assays for containment and management. As many biomarkers are being discovered and validated, there is a higher probability of the development of new diagnostic tests. At present, there are only a few multiplex assays targeting specific disease classes. With the development of new biomarkers, new multiplex assays can be developed. Owing to this, biomarker validation can create opportunities for the development of the multiplex assays market. However, high instrument cost is a major factor limiting the wider adoption of multiplex assays.
“The consumables segment accounted for the highest growth rate in the multiplex assays market, by product & service, during the forecast period”
Based on product & service, the multiplex assays market is segmented into three broad categories, namely, consumables, instruments, and software & services. In 2022, the consumables segment accounted for the largest share of the market. This segment is also expected to grow at the highest CAGR. The instruments segment accounted for the second largest share of the multiplex assays market. The increasing incidence of infectious diseases & cancer, growing demand for automated and advanced instruments with high-throughput capacities and increasing need for faster and more accurate test results with minimal human intervention are driving the instruments market segment.
“The research & development segment accounted for the highest growth rate in the multiplex assays market, by application, during the forecast period”
Based on applications, the multiplex assays market is segmented into research & development (drug discovery & development and biomarker discovery & validation) and clinical diagnostics (infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism & endocrinology disorders, and other diseases). The research & development application segment accounted the largest share of the multiplex assays market in 2022. The drug discovery & development segment accounted for the largest share of the multiplex assays market for research & development in 2022. The demand for multiplex assays in drug discovery & development has increased due to their benefits. These assays tend to be effective in evaluating drug response biomarkers, immunotherapy success, and toxicity during the clinical stages of drug development.

“Asia Pacific: The fastest-growing region multiplex assays market”
The global multiplex assays market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as growing government efforts to increase awareness about the early detection of diseases and the increasing number of regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and growing strength in the research base for diagnostic procedures across India, China, and Japan.

The break-up of the profile of primary participants in the multiplex assays market:

• By Company Type: Tier 1 - 42%, Tier 2 - 37%, and Tier 3 - 21%
• By Designation: C-level - 34%, D-level - 42%, and Others - 24%
• By Region: North America - 32%, Europe - 30%, Asia Pacific - 24%, and the Rest of the World – 14%
The key players in this market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), QIAGEN N.V. (Netherlands), Abcam plc (UK), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Quanterix (US), Bio-Techne (US), MESO SCALE DIAGNOSTICS, LLC (US), Randox Laboratories Ltd. (UK), Olink (Sweden), Seegene Inc. (South Korea), Siemens Healthcare AG (Germany), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Promega Corporation (US), Enzo Biochem Inc. (US), Cayman Chemical (US), Boster Biological Technology (US), Antigenix America, Inc. (US), Quansys Biosciences Inc. (US), and RayBiotech Life, Inc. (US).
Research Coverage:
This research report categorizes the multiplex assays market by product & service (consumables, instruments, and software & services), type (protein multiplex assays [planar protein assays, bead-based protein assays, and other protein assays], nucleic acid multiplex assays [planar nucleic acid assays, bead-based nucleic acid assays, and other nucleic acid assays], and cell-based Multiplex Assays), technology (flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies), application (research & development [drug discovery & development and biomarker discovery & validation] and clinical diagnostics [infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, and metabolism & endocrinology disorders, and other diseases]), end user (pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories, and other end users), and region (North America, Europe, Asia Pacific, and the Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the multiplex assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product & service launches, and recent developments associated with the multiplex assays market. Competitive analysis of upcoming startups in the multiplex assays market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall multiplex assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (increasing use of multiplex assays in companion diagnostics, increasing advantages over singleplex and traditional assays, and increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis), restraints (rising costs of equipment and growing number of stringent regulations and standards), opportunities (increasing validation of biomarkers in molecular and protein diagnostics and rising need for high-throughput and automated systems), and challenges (increasing dearth of skilled professionals) influencing the growth of the multiplex assays market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assays market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the multiplex assays market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the multiplex assays market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany) among others in the multiplex assays market strategies.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?